Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Fineline Cube Aug 20, 2026
Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Fineline Cube Aug 20, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Medical Device

NMPA Approves Hangzhou Ruidi Biotechnology’s Steep Pulse Therapy Equipment for Tumor Treatment

Fineline Cube Nov 29, 2024

China’s National Medical Products Administration (NMPA) has granted approval to Hangzhou Ruidi Biotechnology Co., Ltd...

Company Drug

CDE Expands Care Plan with Approvals for Ractigen’s RAG-17 and Vitalgen’s VGR-R01

Fineline Cube Nov 29, 2024

In a swift succession of actions, China’s Center for Drug Evaluation (CDE) has added two...

Policy / Regulatory

NMPA Drafts Medical Representative Management Measures, Seeks Public Input

Fineline Cube Nov 29, 2024

The National Medical Products Administration (NMPA) has released the “Medical Representative Management Measures (draft proposal)”,...

Company Deals

Daiichi Sankyo Invests RMB 1.1 Billion in New ADC Manufacturing Plant in Shanghai

Fineline Cube Nov 29, 2024

Japanese pharmaceutical company Daiichi Sankyo (TYO: 4568) is significantly increasing its investment in China with...

Company Drug

Jiangsu Kanion Pharmaceutical Gets NMPA Clearance for Oncolytic Virus Product KYS202003A

Fineline Cube Nov 29, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced that it has received clinical clearance...

Company Deals

Lingyi Biotechnology and Jolly Pharmaceutical Ink Comprehensive Collaboration Agreement

Fineline Cube Nov 29, 2024

China-based gene therapy specialist Lingyi Biotechnology Co., Ltd has entered into a comprehensive collaboration agreement...

Company Drug

Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials

Fineline Cube Nov 29, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Deals

Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea

Fineline Cube Nov 29, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...

Company Drug

Laekna, Inc. Initiates IND-Enabling Study for Monoclonal Antibody LAE123 in Severe Diseases

Fineline Cube Nov 29, 2024

Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced the initiation of an Investigational New...

Company Deals

CORXEL Partners with Apeloa Pharmaceutical for CDMO Services Expansion

Fineline Cube Nov 29, 2024

China-based contract development and manufacturing organization (CDMO) Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced...

Company Deals

Wuhan Union Hospital to Transfer Hereditary Thrombophilia Detection Patent to Kingmed Diagnostics

Fineline Cube Nov 29, 2024

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, also recognized as Wuhan...

Company Deals

Shanghai Yanyin Technology Partners with Castalysis Bioscience to Advance CRISPR Software Development

Fineline Cube Nov 29, 2024

Shanghai Yanyin Technology Co., Ltd has announced a strategic partnership with Castalysis Bioscience (Shanghai), a...

Company Drug

Eisai and Biogen Launch Alzheimer’s Treatment Leqembi in South Korea

Fineline Cube Nov 29, 2024

Partners Eisai Co., Ltd (TYO: 4523) and Biogen Inc. (NASDAQ: BIIB) have jointly announced the...

Company

Bayer AG Launches Bayer Co.Lab Berlin, Focusing on Life Science Innovation

Fineline Cube Nov 29, 2024

Germany-based Bayer AG (ETR: BAYN) has announced the opening of its new life science incubator,...

Policy / Regulatory

Chinese Pharmacopoeia Commission Approves Draft for ChP 2025 Edition

Fineline Cube Nov 29, 2024

On December 27, the 12th Conference of the Chinese Pharmacopoeia Commission (ChPC) Executive Committee concluded...

Company Drug

Huadong Medicine’s Arcalyst Receives NMPA Approval for Cryopyrin-Associated Periodic Syndromes

Fineline Cube Nov 28, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing approval from the National...

Company Drug

Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment

Fineline Cube Nov 28, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval...

Company Drug

MicuRx Pharmaceuticals’ MRX-4 Combo Shows Positive Results in Phase III Study

Fineline Cube Nov 28, 2024

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced positive results from a Phase III...

Policy / Regulatory

National Reimbursement Drug List 2024 Expands Coverage with 91 New Drugs

Fineline Cube Nov 28, 2024

The National Medical Products Administration has released the finalized National Reimbursement Drug List (NRDL) for...

Company Deals

Allink Biotherapeutics Secures $42 Million in Series A Financing to Advance Bispecific Antibodies and ADCs

Fineline Cube Nov 28, 2024

Shanghai-based Allink Biotherapeutics, a clinical-stage biotech company specializing in the development of bispecific antibodies (BsAbs)...

Posts pagination

1 … 301 302 303 … 710

Recent updates

  • Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review
  • China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year
  • CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
  • Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light
  • VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Company

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030

Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.